Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Jun 2017 Planned initiation date changed from 1 Jul 2015 to 7 Aug 2015.
- 07 Oct 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.